Teplizumab treatment for stage 2 type 1 diabetes: a real-world evaluation of metabolic and immunological outcomes

Key Points

• Evaluate the effectiveness and safety of teplizumab in managing metabolic and immunological outcomes for stage 2 type 1 diabetes.
• Administered teplizumab in a clinical setting
• Monitored glycaemic control
• Assessed immunological changes related to CD4 TCRs
• Observed early improvements in glycaemic levels
• Noted significant reductions in CD4 preproinsulin-specific TCRs
• Immunological changes may serve as potential biomarkers for early intervention